View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Haselmeier
15 November 2017

Organisational Changes in Quality Management at Haselmeier

Konrad Betzler was appointed the new chief quality officer (CQO) of the entire Haselmeier  Group in October 2017, with responsibility for quality management, quality assurance, and all  regulatory matters worldwide.

As a member of the Group Executive Board, he continues to lead the Pharmaceutical Manufacturing division as chief pharmaceutical officer (CPO).

Former CQO Dr. Bernhard Kraus decided to quit his job at Haselmeier after two years with the Haselmeier Group for personal reasons and to accept new challenges. The Haselmeier team would like to thank him for his committed and successful work in the stabilisation and further development of the company’s global quality management system and wishes him all the best on his further journey.

As CPO in the senior leadership team and as a future Qualified Person responsible for the development of pharmaceutical production at the site in Buchen, Mr. Konrad Betzler took on the position of CQO on 1 October. This gives Haselmeier the unique opportunity to bundle and structure the requirements for the quality management system in one function from the perspective of medical device and drug manufacturing.

As a manufacturer of medical devices, Haselmeier is once again adapting to the increasing demands of the market for combination products and thus qualifies further in the direction of strategic partners for its customers in the pharmaceutical industry.

Although both the medical device and the pharmaceutical industry have different pronouncements, both work in the same process and compliance worlds: rule-based, very structured, facts-based, and transparent. With this step, Haselmeier will help exploit the synergetic potential of combination products and further expand the accompanying quality assurance systems as an integrated partner for its customers.

Based on this consideration, Mr. Betzler also derives his priorities for the next few months:

  • Further developing and integrating the various processes of the quality management system into a holistic, global approach
  • The sustainable implementation of quality indicators as a basis for management decisions
  • The regular exchange with the customers regarding expectations and experiences with Haselmeier.

Mr. Konrad Betzler is looking forward to the personal exchange with his quality management colleagues of our customers. Corresponding appointments are currently active.

Type 2 diabetes is a global health problem. According to expert estimates, the number of patients worldwide will increase by 48% by 2045.
The D-Flex injection pen can do more than previous pens. D-Flex can be configured for several fixed-dose values and is thus a variable fixed-dose pen.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology